http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010147274-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e71c17ec6e47dd48a6dd4f316d2c0fb5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3e873049d3c17d8f9daf737f81c3280e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8e3a9dc46b479c254a7b10fa988284a |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-475 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5044 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 |
| filingDate | 2009-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61e6c44ab9139d01d41f963d410d7cdf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c5b9cfe6b5d1e82d4ca007ac66d4c08 |
| publicationDate | 2010-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2010147274-A1 |
| titleOfInvention | Secretory granules and granulogenic factors as a target for cancer treatment |
| abstract | The present invention relates to a method for screening a cancer therapeutic agent, comprising the steps of: (a) contacting a test substance of interest with a cell containing a granulogenic factor-encoding nucleotide sequence; and (b) analyzing expression of the granulogenic factor or production of secretory granules, wherein the test substance is determined as the cancer therapeutic agent where it inhibits the expression of the granulogenic factor or the production of secretory granules. In the present invention, the expression of the granulogenic factor contributes to induction of secretory granule formation in non-secretory cells, and inhibition of the granulogenic factor expression leads to inhibition of secretory granule formation in secretory cells. In addition, the secretory granules produced by the present granulogenic factor change cell activities via the IP3-dependent cellular Ca2+ regulatory mechanism, and the changes of cellular Ca2+ homeostasis will affect the development and proliferation of cancer cells. Therefore, a pharmaceutical composition containing as an active ingredient a substance which inhibits expression of a granulogenic factor gene, production of secretory granules, or activity of the granulogenic factor may be utilized in cancer prophylaxis or treatment, and also be used as a kit for identifying a cancer. |
| priorityDate | 2009-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 179.